| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary target of Relcovaptan is the vasopressin V1a receptor. It acts as a selective antagonist, blocking the binding of arginine vasopressin (AVP) to this receptor. V1a receptors are involved in the regulation of vascular tone, platelet aggregation, and other physiological processes. By antagonizing the V1a receptor, Relcovaptan can modulate the effects of AVP, which is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF).
|
|---|---|
| ln Vitro |
In vitro, Relcovaptan is a potent and selective antagonist of the vasopressin V1a receptor. Its activity is characterized by its ability to inhibit the binding of AVP to the V1a receptor and to block AVP-induced signaling. The compound's selectivity for the V1a receptor over other vasopressin receptor subtypes (V1b, V2) is confirmed in radioligand binding and functional assays.
|
| ln Vivo |
Early injection following middle cerebral artery (MCA) occlusion showed neuroprotection against ischemic brain injury when SR 49059 (SR-49059) (2 mg/kg and 30 mg/kg; i.p.; once) was administered [2].
In vivo, Relcovaptan has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis. It has also been investigated for its potential in treating congestive heart failure. As a selective V1a receptor antagonist, it can modulate the effects of AVP on vascular tone and water retention, offering therapeutic benefits in these conditions. |
| Enzyme Assay |
In vitro receptor binding studies for Relcovaptan measure its affinity for the vasopressin V1a receptor. Radioligand competition assays are performed using membrane preparations from cells expressing the human V1a receptor. The compound competes with a labeled AVP ligand for binding, and the Ki or IC₅₀ values are determined. Selectivity over V1b and V2 receptors is assessed to confirm its specificity.
|
| Cell Assay |
In vitro cell-based assays for Relcovaptan evaluate its functional antagonism at the V1a receptor. Cells expressing the V1a receptor are treated with an AVP agonist in the presence or absence of Relcovaptan. Receptor activation is measured by downstream signaling, such as intracellular calcium mobilization. The compound's ability to block the agonist-induced response is measured, and IC₅₀ values are determined.
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rat, weight 300 to 350 g, focal cerebral ischemia model [2]
Doses: 2 mg/kg and 30 mg/kg dissolved in 10% dimethyl sulfoxide Route of Administration: intraperitoneal (ip) injection, Primary Experimental Results: Measured infarct volume was Dramatically diminished 48 hrs (hrs (hours)) after arterial occlusion. Reduce neurological deficits and ischemic brain edema. In vivo animal studies for Relcovaptan are conducted in models of cardiovascular and reproductive disorders. The compound is administered orally or intravenously. Its effects on blood pressure, uterine contraction, and other parameters are assessed. Efficacy studies are performed in models of Raynaud's disease, dysmenorrhoea, and preterm labor. Pharmacokinetic studies determine the compound's half-life and bioavailability. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Relcovaptan have been characterized in preclinical and clinical studies. The compound has a molecular weight of 575.0 g/mol. Its solubility is approximately 9.3e-3 g/L (25 ºC). For research use, it is typically stored as a powder at -20°C. Further details on its half-life, Cmax, and bioavailability are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Relcovaptan has been evaluated in preclinical and clinical studies. As a vasopressin receptor antagonist, its potential side effects may include fluid imbalance and hypotension. The compound is for research use only and is not intended for human therapeutic applications without proper authorization.
|
| References |
|
| Additional Infomation |
(2S)-1-[[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indol-2-yl]-oxymethyl]-2-pyrrolidinecarboxamide is a proline derivative.
Additional information: Relcovaptan is also known as SR 49059. Its IUPAC name is (2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide. It is a selective vasopressin V1A receptor antagonist. This product is for research use only and is not approved for clinical or therapeutic applications. |
| Molecular Formula |
C28H27CL2N3O7S
|
|---|---|
| Molecular Weight |
620.49
|
| Exact Mass |
619.095
|
| CAS # |
150375-75-0
|
| PubChem CID |
60943
|
| Appearance |
White to off-white solid powder
|
| Density |
1.499g/cm3
|
| Boiling Point |
868ºC at 760mmHg
|
| Flash Point |
478.8ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
5.084
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
41
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
COC1=C(C=C(C=C1)S(=O)(=O)N2[C@H]([C@](C3=C2C=CC(=C3)Cl)(C4=CC=CC=C4Cl)O)C(=O)N5CCC[C@H]5C(=O)N)OC
|
| InChi Key |
CEBYCSRFKCEUSW-NAYZPBBASA-N
|
| InChi Code |
InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
|
| Chemical Name |
(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
|
| Synonyms |
Relcovaptan SR 49059 SR49059SR-49059
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~161.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6116 mL | 8.0581 mL | 16.1163 mL | |
| 5 mM | 0.3223 mL | 1.6116 mL | 3.2233 mL | |
| 10 mM | 0.1612 mL | 0.8058 mL | 1.6116 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
